Gut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke

Area of Science:

• Cardiovascular Research
• Metabolomics
• Neurology

Background:

• Trimethylamine-N-oxide (TMAO) is a gut microbiota-derived metabolite.
• Elevated TMAO levels correlate with increased cardiovascular disease risk.
• Emerging evidence links TMAO to the pathogenesis of ischemic stroke.

Purpose of the Study:

• To review the relationship between TMAO and ischemic stroke risk factors, disease progression, and outcomes.
• To elucidate the mechanisms underlying TMAO's role in ischemic stroke.
• To evaluate interventions targeting the gut microbiota-TMAO pathway for stroke prevention and treatment.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies.
• Analysis of TMAO's impact on atherosclerosis, thrombosis, and endothelial function.
• Evaluation of studies investigating gut microbiota modulation for TMAO reduction.

Main Results:

• TMAO promotes atherosclerosis and thrombosis via lipid metabolism, foam cell formation, and endothelial dysfunction.
• TMAO enhances platelet hyper-reactivity and vascular endothelial tissue factor activation.
• Mechanisms for TMAO's effect on stroke severity and recovery may involve inflammation and immune cell modulation.

Conclusions:

• TMAO is a significant factor in ischemic stroke development and progression.
• Targeting the gut microbiota-TMAO axis presents a promising therapeutic strategy for ischemic stroke.
• Further research is needed to clarify TMAO's precise role in stroke severity and neurological recovery.